3 Trial Losses Won't Doom Xarelto Patients
After a hat trick of defense wins for Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. in bellwether trials over blood thinner Xarelto, consumers face an uphill...To view the full article, register now.
Already a subscriber? Click here to view full article